Huang Chun-Cheng, Wang Chih-Hsien, Chou Heng-Wen, Chi Nai-Hsin, Yu Hsi-Yu, Chen Yih-Sharng
Department of Surgery, National Taiwan University Hospital, and College of Medicine, National Taiwan University, Taipei, Taiwan, ROC.
Artif Organs. 2023 Jan;47(1):205-213. doi: 10.1111/aor.14417. Epub 2022 Oct 20.
Pulmonary artery (PA) cannulation is an effective extracorporeal life support (ECLS) management for left ventricular (LV) decompression or right ventricular (RV) support. This case series explores the results of PA cannulation during ECLS for acute cardiac failure.
Patients receiving percutaneous PA cannulation between January 2017 and December 2020 in a single institution were retrospectively reviewed. Patients receiving PA cannulation by a surgical cutdown method were excluded. Based on the hemodynamic needs of the patients, percutaneous PA cannulation was applied with ECLS for LV unloading and/or RV support. The primary endpoint was the successful weaning from circulatory support. The secondary endpoints included 30-day or in-hospital mortality, significant periprocedural complications, and successful hospital discharge without major complications.
Fifteen patients (13 men, age range 11.2-70.8 years) presented acute heart failure and were initially managed by conventional ECLS mode. Percutaneous PA cannulation was performed for LV unloading in 13 patients (86.67%) and isolated RV circulatory support in two patients (13.33%). Weaning from circulatory support was achieved in 11 patients (73.33%). No significant periprocedural complication, including bleeding, infection, or vascular event requiring surgical exploration, was reported. The 30-day or in-hospital mortality rate was 33.33%. Eight cases (53.33%) were successfully discharged without major complications, including permanent stroke or the need for long-term hemodialysis.
PA cannulation, especially percutaneously performed, was effective and safe for LV unloading and/or RV support during ECLS. Further investigation is required to confirm the efficacy and safety of our approach and management in a larger patient population.
肺动脉插管是一种用于左心室减压或右心室支持的有效体外生命支持(ECLS)管理方法。本病例系列探讨了在急性心力衰竭的ECLS期间进行肺动脉插管的结果。
回顾性分析2017年1月至2020年12月在单一机构接受经皮肺动脉插管的患者。排除通过手术切开方法进行肺动脉插管的患者。根据患者的血流动力学需求,将经皮肺动脉插管与ECLS联合应用于左心室卸载和/或右心室支持。主要终点是成功脱离循环支持。次要终点包括30天或住院死亡率、围手术期严重并发症以及无重大并发症的成功出院。
15例患者(13例男性,年龄范围11.2 - 70.8岁)出现急性心力衰竭,最初采用传统ECLS模式进行管理。13例患者(86.67%)进行经皮肺动脉插管以进行左心室卸载,2例患者(13.33%)进行单纯右心室循环支持。11例患者(73.33%)成功脱离循环支持。未报告围手术期严重并发症,包括出血、感染或需要手术探查的血管事件。30天或住院死亡率为33.33%。8例患者(53.33%)成功出院,无重大并发症,包括永久性中风或长期血液透析需求。
肺动脉插管,尤其是经皮进行的,在ECLS期间用于左心室卸载和/或右心室支持是有效且安全的。需要进一步研究以在更大的患者群体中证实我们的方法和管理的有效性和安全性。